Our Comparative Advantage lies in our in-house transversal expertise from a pharma, clinical, public health, basic science, and a payer perspective, with diverse geographic origins.
The team is supported by our network of international HTA experts and decision-makers.
We work throughout the development phase of a product up to the negotiation with payers, with a special focus on disruptive innovations.
We specialize in
Early engagement (trade off assessment & study designs, as early as POC studies)
Health Technology Assessment (HTA)
Patient access
Pricing and Reimbursement (P&R)Strategic advice for payer organizations & Governments
Our core competence
Early assessment
Phase 1
Phase 2
02.
Parallel/early Scientific Advice
Official HAS/EMA/EUnetHTA
Mock Parallel/early Scientific Advice
03.
3A. Flash Advice for due diligence on a TPP
3B. Best prepare for 2025 EU Clinical effectiveness assessment
Pre-Submission advice
Phase 3
Pre-launch
Launch
Leadership team
OUR GLOBAL EXPERT NETWORK
36
Countries covered
220
Payer & HTA experts
